Pancreatic Cancer Research

ResearcherInsermNo recent work listed

André Pèlegrin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9254-2648; OpenAlex author ID A5082011377. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 8

  1. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1168444↗
  2. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. Co-author DOI 10.1080/19420862.2021.1914883↗
  3. An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. Co-author DOI 10.1002/ijc.32273↗
  4. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical model… Co-author DOI 10.1016/j.canlet.2018.06.023↗
  5. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infr… Co-author DOI 10.1245/s10434-018-6655-7↗
  6. Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "TH… Last author DOI 10.18632/oncotarget.3473↗
  7. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Co-author DOI 10.1038/onc.2013.487↗
  8. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Co-author DOI 10.18632/oncotarget.2231↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christel Larbouret · 7 shared papers, 2014–2023 · strength 0.50
  2. Thierry Chardès · 6 shared papers, 2014–2023 · strength 0.46
  3. Pierre‐Emmanuel Colombo · 4 shared papers, 2014–2021 · strength 0.28
  4. Emilia Rabia · 2 shared papers, 2021–2023 · strength 0.24
  5. Bruno Robert · 4 shared papers, 2014–2018 · strength 0.18
  6. Charline Ogier · 2 shared papers, 2018–2019 · strength 0.14
  7. Gaëlle Thomas · 3 shared papers, 2014–2018 · strength 0.13
  8. Marine Bruciamacchie · 1 shared paper, 2021 · strength 0.10
  9. Laura Bourillon · 1 shared paper, 2019 · strength 0.08
  10. Wilhem Leconet · 2 shared papers, 2014 · strength 0.07
  11. Charlotte E.S. Hoogstins · 1 shared paper, 2018 · strength 0.07
  12. Babs G. Sibinga Mulder · 1 shared paper, 2018 · strength 0.07
  13. Bert A. Bonsing · 1 shared paper, 2018 · strength 0.07
  14. J. Sven D. Mieog · 1 shared paper, 2018 · strength 0.07
  15. Rutger‐Jan Swijnenburg · 1 shared paper, 2018 · strength 0.07
  16. Alexander L. Vahrmeijer · 1 shared paper, 2018 · strength 0.07
  17. Corinne Bousquet · 1 shared paper, 2018 · strength 0.06
  18. Marc Ychou · 1 shared paper, 2015 · strength 0.04
  19. Eric Assénat · 1 shared paper, 2015 · strength 0.04
  20. Fabienne Portales · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.